Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease (NCT06489548)
Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated by PET Imaging in Patients With Early Symptomatic Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen. Previous data on experimental mice has suggested that Foralumab increases the immune system activity in the brain to reduce the inflammation of microglia, the brain's main immune cells. This combination of increased immune reactivity and less microglia inflammation may improve the immune response throughout the brain. Alzheimer's disease and other forms of dementia are characteristically known for the build-up of certain proteins in the brain. This trial will evaluate whether nasal Foralumab can improve cognition in participants with mild cognitive impairment due to early Alzheimer's or dementia. The trial will ask participants to administer Foralumab nasally three times a week for eight weeks. The administration will occur intermittently, with breaks between each dosing cycle. Participants will also receive brain scans (Amyloid PET and MRI), undergo cognitive testing, blood draws, and physical, neurological, and nasal exams. Volunteers are expected to remain in the trial for six months.
Who can join: Review the eligibility criteria below.
Location: Center for Alzheimer Research and Treatment, Brigham and Women's Hospital — Boston, Massachusetts
Age range: 60 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 525-6754
Email: foralumab@mgb.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dementia
- A Virtual Reality at Home Intervention for People Living With Dementia — Toronto, Ontario
- Caregiver Bootcamp — Atlanta, Georgia
- A Spanish-language Caregiver-Enabled Care Program — Carlsbad, California
- The Sunnybrook Dementia Study — Toronto, Ontario
- Palliative Care for Patients With Dementia — New York, New York
- Cognitive Health Awareness Program in Surgical Patients — Toronto, Ontario
Explore by condition: All Dementia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.